Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Advaxis, Inc. (Nasdaq: ADXS) announced its participation at the 35th Annual Meeting of the Society for Immunology of Cancer (SITC 2020), presenting an ePoster on November 12th and 14th. The presentation will focus on a Phase 1/2 study of ADXS-503, a multi-neoantigen vector, alone and with Pembrolizumab in metastatic non-small cell lung cancer (NSCLC). This innovative immunotherapy product utilizes bioengineered Listeria monocytogenes to stimulate anti-tumor T cell immunity. For more details, the poster will be accessible on Advaxis' website.
Positive
- Presentation of significant clinical study results at SITC 2020.
- Focus on an innovative treatment approach for metastatic NSCLC.
- Engagement with scientific community through ePoster.
Negative
- None.
Details
News Market Reaction – ADXS
The recorded move for ADXS in the trading session of this news was +7.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it will present an ePoster at the 35th Annual Meeting of the Society for Immunology of Cancer (SITC 2020) to be held virtually November 9-14, 2020.
Title: “Phase 1/2 Study of an Off-the-Shelf, Multi-Neoantigen Vector (ADXS-503) Alone and in Combination with Pembrolizumab in Subjects with Metastatic Non-Small Cell Lung Cancer (NSCLC)”
Presenter: Dr. Jonathan W. Goldman. University of California Los Angeles, Santa Monica, CA
Abstract ID: 360
Date and Time: Thursday, November 12th from 4:50 pm until 5:20 pm ET and Saturday, November 14th from 1:00 pm until 1:30 pm ET.
The poster will be available on Advaxis’ website at https://www.advaxis.com/events-and-presentations
About Advaxis, Inc.
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.
To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.
Investor Contact
Tim McCarthy
LifeSci Advisors, LLC
Tim@lifesciadvisors.com
(212) 915-2564
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.